Why is Chugai Pharmaceutical stock sliding today?
Chugai Pharmaceutical shares experienced a 2.5% decline on Tuesday, closing at ¥6,203, following the company's announcement that it would halt the development of GYM329 obesity drugs and return all licensing rights to Roche. This decision resulted from the Phase II trial's failure to demonstrate clinically meaningful weight loss, exacerbating existing concerns arising from Chugai's second-quarter results.
These results fell short of market expectations, with core operating profit 5% below consensus, Hemlibra export revenues lagging, and Foundayo royalties underperforming. The stock's recent decline from its 52-week high of ¥10,700 further added to the pressure. Investors remain cautious ahead of the upcoming earnings report on October 27, 2026, as the broader Nikkei 225 index also dipped 1% on the same day.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
